Business Wire

Mauna Kea Technologies: Cellvizio® Now Recommended in New European Society of Gastrointestinal Endoscopy Technical Guideline for Pancreatic Cyst Diagnosis

PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p ...
Business Wire

Mauna Kea Technologies and Endotherapeutics Announce Cellvizio® First Australian Orders, Advancing CellTolerance® Commercial Expansion

PARIS & BOSTON & SYDNEY--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT) and Endotherapeutics, today announced that Cellvizio system has been included in the ...
Seeking Alpha

Mauna Kea Technologies Reports Full Year 2024 Results and Provides a Business Update

Recently approved safeguard proceeding yielding productive creditor and investor discussions aimed at strengthening Mauna Kea’s long-term financial position Currently in exclusive negotiations phase ...
Seeking Alpha

Mauna Kea Technologies Announces Major AI Breakthrough with Cellvizio in Pancreatic Cystic Lesion Risk Stratification

Results build on new CLIMB study data recently presented at Digestive Disease Week ® (DDW) 1 confirming Cellvizio ® ’s unmatched accuracy in pancreatic cyst diagnosis PARIS & BOSTON--(BUSINESS WIRE)-- ...
Morningstar

Mauna Kea Technologies Announces Entrance Into Exclusive Negotiations for a Licensing Agreement for Cellvizio® in an Important Therapeutic Area With a Major Industry Player

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces entering into ...